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A random population-based sample of 131 subjects was used to assess the value of serum eosinophil cationic 
protein (ECP), serum myeloperioxidase (MPO), and urinary leukotriene E4 (LTE,) in predicting bronchial hyper- 
responsiveness measured by methacholine challenge. Special interest was focused on the history of aspirin 
intolerance and on smoking as contributing factors. 
The mean serum ECP and MPO were higher in hyper-reactive [provocational dose causing a 20% fall in forced 
expiratory volume in 1 sec. (PD& < 6900 pg] than in non-hyper-reactive subjects (22.3 vs. 13.2 pg l-‘, P<O.OOl 
and 377 vs. 278 pg l-‘, P= 0.001, respectively). This was also seen in current smokers vs. never smokers (17.2 vs. 
12.9 lg l-‘, P= 0.03 and 372 vs. 286 pg l-‘, P=O.O4, respectively). There were no differences in baseline urinary 
excretion of LTE4 between hyper-reactive and non-hyper-reactive subjects. During the 2 h after methacholine 
challenge, urinary LTE4 excretion increased from 53.8 and 69.0 ng mmol-’ creatinine in non-hyper-reactive 
subjects, but there was no change in hyper-reactive subjects (non-hyper-reactive vs. hyper-reactive, P= 0.06). The 
increase was greatest in subjects with aspirin intolerance causing urticaria or angioedema but not aggravation of 
asthma (from 58.5 to 87.2 ng mmol-’ creatinine), probably due to extrapuhnonary leukotriene production. 
Our results indicate that serum ECP and MPO, but not urinary LTE4 (even in subjects with a history of aspirin 
intolerance), predict bronchial hyper-responsiveness to methacholine. The subject’s smoking history must be taken 
into account when these parameters are considered. 
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Introduction 
Bronchial hyper-responsiveness to methacholine or hista- 
mine is closely associated with asthma but is also found in 
several other airway disorders, as well as in healthy 
individuals (l-4). Asthma is characterized by chronic 
inflammatory changes in the airway mucosa, even in its 
mildest form (5). The infiltration of inflammatory cells in 
the lamina propria of the airways of asthmatic patients has 
been shown to be inversely related to provocational 
concentration causing a 20% fall in forced expiratory 
volume’ in 1 set (PC,,) for methacholine (6), but in atopic 
subjects with mild to moderate asthma no correlation has 
been found between the degree of airway responsiveness 
and the numbers of inflammatory cells in sputum or 
bronchoalveolar lavage or bronchial biopsy (7). To monitor 
airway inflammation other markers have also been studied. 
Myeloperoxidase (MPO), as a parameter of neutrophil 
activity, and eosinophil cationic protein (ECP), as a 
parameter of eosinophil activity, are both elevated in 
induced sputum in patients with asthma and chronic 
obstructive pulmonary disease (COPD) (8,9). In COPD, 
the changes in MPO seem to be more prominent (8). Serum 
ECP and MPO are elevated in children with persistent 
asthma symptoms (10,ll). Further, serum ECP, but not 
serum MPO, is influenced by atopy and eczema states 
(10,ll). 
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In asthmatic subjects, plasma leukotriene E4(LTE4) levels 
have been shown to be higher than in controls and are 
related to disease activity (12). In contrast, baseline values 
for urinary LTE4, which is an index of whole-body 
production of cysteinyl-leukotrienes, do not differ between 
atopic asthmatics and non-asthmatics (13). Elevated basal 
urinary LTEd excretion has been reported in aspirin- 
intolerant asthmatics (13,14). LTE4 excretion has been 
increased after aspirin challenge in aspirin-intolerant 
asthmatics, but methacholine challenge producing compar- 
able bronchial obstruction did not alter eicosanoid excre- 
tion (15). 
The aim of the present study was to use random 
population-based material to assess the .value of serum 
MPO, ECP and urinary LTE4 in indicating bronchial 
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hyper-responsiveness as measured by methacholine chal- 
lenge. Special interest was focussed on the history of aspirin 
intolerance and on smoking as contributing factors. 
Methods 
POPULATION SAMPLES 
The original study population comprised a population- 
based random sample (4300) of adult women and men, 
aged 18-65 years served by the Paijat-Hame Central 
Hospital (16). Of these subjects, 3102 returned a postal 
questionaire, yielding a response rate of 73%. Special 
interest was focused on markers of intrinsic asthma (16). 
The study groups of the present study were as follows. 
Group 1: Subjects with a History of Aspirin 
Intolerance Causing Shortness of Breath or 
Worsening of Asthma 
The population-based sample (4300) included a total of 35 
subjects with symptoms consistent with the group defini- 
tion. A trained nurse interviewed 32 of these subjects and 29 
of them were confirmed to have aspirin intolerance. 
Twenty-two of these participated in the study proper. Ten 
subjects (46%) had doctor-diagnosed asthma and seven had 
been on inhaled steroid treatment. 
Group 2: Subjects with a History of Aspirin 
Intolerance Causing Urticaria or Angioedema but 
not Respiratory Symptoms 
The population-based sample included 50 subjects fulfilling 
these criteria and 39 of these were interviewed. Thirty-two 
has confirmed positive history and 24 took part in the 
study. 
Group 3: Subjects with Doctor-Diagnosed Asthma 
and Without a Histo y of Aspirin Intolerance 
The population-based sample included 93 subjects in this 
category. A random sample of 39 subjects participated in 
the study. Twenty-two of them had been on inhaled steroid 
treatment. 
Group 4: Subjects with a History of Symptoms of 
Asthma or Attacks of Shortness of Breath in the 
Past 22 Months Without Asthma or Other 
Respiratory Diagnosis, no Medication and no 
History of Aspirin Intolerance 
The population-based sample included 197 such subjects. A 
random sample of 27 participated in the study. 
Group 5: Subjects Without a Histo y of Respirato y 
Symptoms and Without Aspirin Intolerance 
The population-based sample included 1510 such subjects. 
A random sample of 19 participated in the study. 
Twenty-six per cent of all subjects were regular smokers, 
43% were irregular smokers or had stopped smoking and 
3 1% were never-smokers. 
The study was approved by Ethics Committee of Paijast- 
Hame Central Hospital. 
METHACHOLINE CHALLENGES AND 
SPIROMETRY 
A rapid dosimetric methacholine challenge test, performed 
with a pocket turbine spirometer (Micro Spiromete@; 
Micro Medical Instruments Ltd, Rochester, U.K.), was 
employed, its volume calibration being checked with 
calibration pumps as previously described (17). An auto- 
matic, inhalation-synchronized dosimeter jet nebuliser, the 
Spira Elektro 2 (Respiratory Care Center, Hameenlinna, 
Finland), was used for methacholine delivery. Patients had 
to have a forced expiratory volume in 1 set (FEVi) of at 
least 65% of predicted before the challenge and were 
excluded if they had experienced any respiratory infection 
during the previous 4 weeks. Methacholine chloride was 
delivered in four cumulative doses of 80, 400, 1700 and 
6900 ug. The fall in FEVi was plotted against the 
methacholine dose on a log scale, and the provocational 
dose causing a 20% fall in FEVi (PDze) was estimated by 
interpolation from the dose-response cure. The dose- 
response ratio (DRR) was also calculated as the percentage 
fall in FEVi by the last dose, divided by total dose 
administered (18). 
All subjects underwent spirometry and a bell spirometer 
with a water seal (Could 2400°, SencorMedics Corpora- 
tion, Yorba Linda, CA, U.S.A.) was used for lung function 
studies as previously described (19). Measurement of 
volumes and ventilatory flows were corrected to BTPS 
(body temperature, pressure, saturated with water vapour). 
ECP AND MPO CONCENTRATIONS IN 
SERUM 
Venous blood was collected prior to methacholine provo- 
cation in glass Vacutainer tubes without anticoagulants, 
and allowed to clot at 22°C for 60 min. Serum was 
separated by centrifugation (1200 g for 10 min at 22°C) and 
kept at -70°C until analysied. ECP and MPO were 
measured by radiommunoassay using reagents from 
Pharmacia & Upjohn AB (Uppsala, Sweden). 
LTE4 CONCENTRATIONS IN URINE 
Urine samples were collected prior to and for the 2 h 
following the methacholine provocation and kept at - 70°C 
until analysed. LTE4 concentrations were measured in 
serial dilutions by enzyme immunoassay (EIA) using 
SERUM ECP AND MPO IN BRONCHIAL HYPER-RESPONSIVENESS 591 
reagents from Cayman Chemicals as described by Kumlin 
et al. (13). The results are expressed as ng of LTE4 per 
mm01 of creatinine in the urine sample. 
SKIN-PRICK TESTS AND BLOOD 
EOSINOPHILS COUNTS 
Skin-prick tests were carried out on all subjects with a 
panel of 12 common allergen extracts (Soluprick”, ALK A/ 
S, Copenhagen, Denmark) with a negative (solvent) and a 
positive (histamine dihydrochloride, 10 mg ml-‘) control. 
The allergens used were birch, timothy, meadow fescue and 
mugwort pollen; horse, dog, cat and cow dander; the mites 
Dermatophagoides farinae and Dermatophagoides pteronys- 
sinus; and spores of the moulds Alternaria alternata and 
Cladosporium herbarum. A subject was considered atopic if 
any allergen caused a weal size 13 mm, while control 
solutions gave expected results. Venous blood was collected 
and the blood eosinophil counts measured. 
STATISTICAL METHODS 
The study population consisted of five separate groups 
for statistical analysis, groups 1 and 3 were combined to 
form the group of subjects with asthma. This combined 
group was compared to group 4 (asthmatic symptoms 
without respiratory diagnosis) and to group 5 (controls). In 
addition, group 1 (subjects with aspirin intolerance causing 
shortness of breath or worsening of asthma) was compared 
to group 2 (subjects with aspirin intolerance causing 
urticaria or angioedema); and group 4 (asthmatic symp- 
toms without respiratory diagnosis) was compared to group 
5 (controls). In pair-wise comparisons, Fisher’s least 
significant difference method was used and in the case of 
nominal data the &i-squared test was applied. Logarithmic 
transformations were carried out for skewed distributions. 
With respect to quantitative inflammatory parameters, a 
t-test for independent samples was used to compare hyper- 
reactive with non-hyper-reactive subjects and smokers with 
non-smokers. Nominal data were analysed using the chi- 
squared test. Spearman’s rank correlation coefficient was 
used to investigate the correlation between change in 
urinary LTE4 excretion and methacholine dose. 
Sensitivity, specificity and positive and negative predic- 
tive values at different cut-off points were calculated to 
compare serum ECP, MPO and urinary LTE4 as indicators 
of hyper-reactivity. Receiver operator characteristic ROC 
curves for bronchial hyper-responsiveness were constructed 
by plotting sensitivity against 1 -specificity. 
Results 
COMPARISONS BETWEEN THE GROUPS 
Anthropometric data on the subjects are given in Table 1. 
There were no statistically significant differences between 
the groups in this context. 
Data for the methacholine challenges and FEV, mea- 
surements are similarly given in Table 1. There were no 
hyper-reactive subjects (PDZo 5 6900 pg) in groups 2 or 5 
(subjects without a history of asthmatic symptoms). In 
subjects with asthma (groups 1 and 3 together), hyper- 
reactivity (49%) was observed significantly more often than 
in group 4 (asthmatic symptoms without diagnosis, 26%) 
and group 5 (controls, 0%) (P= 0.05 and P= 0.0001, 
respectively). Also, the difference between groups 4 and 5 
was significant (P = 0.02). Among aspirin-intolerant sub- 
jects, hyper-reactivity was significantly more common in 
group 1 (respiratory symptoms) than in group 2 (urticaria 
or angioedema) 38% vs. 0%, P=O.OOl). 
In subjects with asthma, the FEVl % of predicted value 
(FEV1 pred.) was significantly lower (mean 85%) than in 
groups 4 and 5 (P = 0.04 and P= 0.001, respectively). The 
difference between groups 4 and 5 was not significant 
(P = 0.16). Among aspirin-intolerant subjects between 
groups 1 and 2, the difference was not significant (P = 0.67). 
TABLE 1. Anthropometric data, metacholine challenges, and FEVl data for the subjects (n = 131) 
Group 1 Group 2 Group 3 Group 4 Group 5 
Subjects (p) 22 24 39 27 19 
Sex (M/F) 7/15 9115 14125 7120 4115 
Age (years), mean (range) 46 (24-65) 45 (21-66) 50 (20-67) 52 (22-67) 43(25-61) 
PDZO, min-max 32-6900 22-6900 1 l&6900 
(pg methacholine) in hyper-reactive 
subjects 
Hyper-reactive subjects*, n (%) 8121 (38) 0123 (0) 17/30 (57) 
DRR (% kmol-’ methacholine) 
7127 (26) o/19 (0) 
0.51 0.23 0.64 0.40 0.14 
median (range) 
FEVl (l), mean (range) 
FEVl % pred.+, 
mean (range) 
(0.06-85.5) (0*0@-0~45) (0*03-131.9) (0.03-17.6) (0.06-0.42) 
3-09 (1.58-5-38) 3.33 (1.87-5.41) 2.73 2.92 (0.64-5.2) (1.66-4.36) 3.40 (1-734.87) 
92 (62-127) 94 (62-l 13) 82 (27-l 19) 94 (67-123) 101 (81-115) 
*PD2&6900 Fg. 
+See reference (20). 
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TABLE 2. Parameters of airways inflammation and skin-prick tests 
Group 1 Group 2 Group 3 Group 4 Group 5 
Eosinophil count ( x 1091-I), 
median (range) 
Eosinophil count n 
(LO.4 x lo9 1-r>, n (%) 
Serum ECP (ug 1-l) 
median (range) 
Serum ECP, 
(n115 pg 1-l>, n (%) 
Urine LTE4 (ng mmol-’ 
creatinine), median (range) 
Urine LTE4 (n250ng rnrn01-~ 
creatinine), n (%) 
Serum MPO (ug l-l), 
median (range) 
Serum MPO (n>300) 
(F&T 1-9, n (%I 
Skin prick, [n> 1 
positive (>3mm)], n (%) 
0.19 (0-06-1.0) 0.15 (0.03-0.59) 0.23 (0~05-1~09) 0.19 (0.10.74) 0.16 (O.OlH44) 
4122 (18) 2123 (9) lo/39 (26) 3/27 (11) l/l9 (5) 
13.6 (1.8-71.3) 9.2 (2.1-32.3) 16.9 (40949.8) 13.8 (3.3-34-6) 12-O (l-7-25) 
9122 (41) 6124 (25) 24/39 (62) 12/27 (44) S/19 (42) 
40.8 (11.9-184.1) 57.8 (13+3- 47.6 (8-4-307.5) 49.9 (14.3-94.6) 47.5 (20.9-171.6) 
130.6) 
8/22 (36) 15/24 (63) 18/38 (47) 14/27 (52) 9/19 (47) 
262 (120-788) 201 (84540) 338 (133-764) 311 (137-900) 254 (131480) 
9122 (41) 7/24 (29) 22/39 (56) 14/27 (52) 6/19 (32) 
9122 (41) 8124 (33) 16/39 (41) 9127 (33) 7/19 (37) 
Airway inflammation parameters and skin-prick tests are 
given in Table 2. The peripheral eosinophil count was 
higher in asthmatics than in controls (0.29 vs. 0.18 x lo9 
1-l; P=O.Ol) as was serum ECP (18.6 vs. 12.0 ug 1-l 
P = 0.03) and serum MPO (337 vs. 266 ~.tg 1-l; P=O.O6). 
Serum ECP in the non-atopic control group (no positive 
prick tests) was 12.0 ug 1-l (range from 5.8 to 25.0 pg 1-l. 
The other pair-wise comparisons were not significant. With 
respect to urinary LTE4 and atopic status (skin-prick test), 
there were no differences between the groups). 
SERUM ECP, MI’0 AND URINARY LTE4 
AS INDICATORS OF BRONCHIAL 
HYPER-RESPONSIVENESS 
ROC curves for bronchial hyper-responsiveness using 
different cut-off points are given in Fig. 1. The cut-off 
points of 15 ug l- ’ for ECP, 300 pg l- ’ for MPO and 50 mg 
mmol-l creatinine for LTE4 gave the best sensitivity and 
specificity. The mean values of serum ECP, MPO, and 
urinary LTE4 in hyper-reactive and non-hyper-reactive 
subjects are given in Table 3. 
ASSOCIATION BETWEEN SERUM EC-P AND 
BRONCHIAL HYI’ERRESPONSIVENESS 
Mean serum ECP was higher in subjects with a positive 
response to methacholine challenge than in those with a 
negative response (Table 3). Mean serum ECP was also 
increased in current or ex-smokers (mean values 17.2 (SD 
9.7) ug 1-l 18.7(12.1) pg l-l, respectively, as compared to 
never-smokers 12.9 (9.0) ug 1-r; P= 0.03 never-smokers vs. 
Current smokers; Fig. 2). 
0.8 
0 
0 0.2 0.4 0.6 0.8 1.0 
1 - specificity 
FIG. 1. Receiver operator characteristic (ROC) curves for 
bronchial hyper-responsiveness using different cut-off 
points [lo, 15, 20, 25 pg 1-l in ECP(n); 200, 250, 300, 
350, 400 L-’ in MPO(A); and 20, 30, 40, 50, 60, 70 ng 
mmol- ’ creatinine in LTEd( O)]. 
Seventy-two per cent of hyper-reactive subjects had 
serum ECP levels 215 pg 1-l as compared to 35% of 
non-hyper-reactive (P = 0.0004; sensitivity 72%, specificity 
65%, positive predictive value 43% and negative predictive 
value 86%). Serum ECP correlated with the blood 
eosinophil count (r= 0.67, P<O.OOOOl). Twenty per cent 
of those with elevated blood eosinophil count (2 0.4 x lo9 
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TABLE 3. The mean values of serum ECP (ug I-‘), MPO (pg 1-l) and 
urinary LTE4 (ng mmol- ’ creatinine) in hyper-reactive (PDae<6900 ug) 
and non-hyper-reactive (PDse > 6900 ug) subjects 
Hyper-reactive Non-hyper-reactive 
subjects subjects r-test: 
(n = 32) (n = 88) P-value 
Serum ECP 
Mean 
SD 
Serum MPO 
Mean 
SD 
Mean Urinary LTE4 
SD 
22.3 13.2 < 0401 
12.8 7.0 
377 278 o%ul7 
181 131 
57.7 53.8 O-64 
51.7 34.8 
I 1 
” ” Never smoker Stopped/irfegnlarC!ment s oker 
FIG. 2. Serum MPO (0) and ECP (m) concentrations in 
the study subjects divided according to smoking history 
(mean f SEM). 
cells l- ‘) had, however, serum ECP < 15 ug l- * and 73% of 
those with serum ECP 2 15 ug I- ’ had a normal blood 
eosinophil count (CO.4 x 10’ cells l- ‘). 
SERUM MPO AND BRONCHIAL 
HYPER-RESPONSIVENESS 
The mean serum MPO was higher in subjects positive to 
methacholine challenge than in those who were negative 
(Table 3). Mean serum MPO was also higher in current or 
ex-smokers [mean values 372 (SD 166) ug 1-l and 304 (134) 
ug l-l], than in never-smokers [286 (166) ug I-‘]; P=O.O4, 
never-smokers vs. current smokers; Fig. 2). 
URINARY LTE4 AND BRONCHIAL 
HYPER-RESPONSIVENESS 
There were no statistically significant differences between 
the study groups in baseline urinary LTE4 excretion (Table 
2). During the 2 h following methacholine challenge, 
urinary LTE4 excretion increased from 53.8 to 69.0 ng 
Aspirin Aspirin 
intoluancc, inloletsact, 
respiraLory skin 
FIG. 3. Change in urinary LTEa concentration 2 h after 
methacholine challenge in the different study groups 
(mean f s~hf). 
IllI-Il01-’ creatinine in non-hyper-reactive subjects, whereas 
there was no change in LTEd excretion in hyper-reactive 
subjects (non-hyper-reactive W. hyper-reactive, P= 0.06). 
There was no correlation between the increase in LTE4 
excretion and methacholine dose (I = O-1 I, P = 0.23). 
Aspirin intolerance was also associated with the change 
in LT& excretion after methocholine challenge. In aspirin- 
intolerant subjects, the urinary LTE4 increased from 55.4 
to 73.9 ng mmol-’ creatinine, while in subjects with no 
history of aspirin intolerance the change was from 54.5 to 
62.5 ng mmol-’ creatinine (aspirin intolerance subjects vs. 
others, P=O.O9). No interaction was detected between 
hyper-reactivity and aspirin intolerance (ANOVA, interac- 
tion P=Oe99). The greatest change in LTE4 was seen in 
subjects with aspirin intolerance causing urticaria or 
angiodema without respiratory side-effects (from 58.5 to 
87.2 ng mmol-’ creatinine, Fig. 3). The mean increase in 
these subjects was 28.7 ng mmol-’ creatinine vs. 7.8 
ng mmol-’ creatinine in other subjects (P=O.O2). The 
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lowest increase, if any, was seen in patients with asthma 
(groups 1 and 3, Fig. 3). 
Discussion 
In this study a random population-based sample group was 
used to assess the value of serum MPO, ECP and urinary 
LTE4 as measures of bronchial hyper-responsiveness. 
Special interest focused on subjects with a history of aspirin 
intolerance, which is associated with the most aggressive 
form of asthma (21); new leukotriene modifiers have been 
shown to be effective in blocking adverse reactions to 
aspirin and other non-steroidal anti-inflammatory drugs 
(NSAID) in susceptible asthmatic patients (22). 
The main purposes in developing inflammatory indices 
for asthma are to help early detection and differential 
diagnosis of the disease and, further, to make possible 
better-targeted treatment as well as follow-up of patients on 
the basis of objective measurements. The need for simple 
parameters to detect and monitor airway inflammation is 
obvious, especially in general practice. The infiltration of 
inflammatory cells into the lamina propria of the airways of 
asthmatic patients has been shown to be inversely related to 
PC20 for methacholine but not clearly to symptoms or 
changes in lung function tests, including peak expiratory 
flow (PEF) variability (6). This finding emphasizes the 
importance of the methacholine test in the follow-up of 
asthmatic patients; however, the test procedures are 
technically challenging and time-consuming and cannot 
easily be expanded to use in general practice. On the other 
hand, some studies have failed to reveal any correlation 
between methacholine responsiveness and the number of 
inflammatory cells evaluated by any method (7). Hence, in 
the treatment of asthma, the assessment of all three 
components, airway obstruction, airway hyperresponsive- 
ness and airway inflammation, has recently been stressed 
(23). 
In this present study, serum ECP and MPO levels were 
higher in hyper-reactive than in non-hyper-reactive sub- 
jects, which confirms findings in previous reports (10,ll). 
Serum ECP has also been shown to correlate with the 
percentage of eosinophils in bronchoalveolar fluid and 
bronchial biopsy specimens and reflects the intensity of 
eosinophil airway inflammation as well as disease activity 
(24). Serum ECP and MPO can thus be used to monitor 
anti-inflammatory treatment in asthmatic patients 
(11,25,26). They are, however, not changed in smoking 
asthmatics even with high-dose budesonide (25) or in 
COPD patients using inhaled steroids (26), which would 
imply that smoking asthmatics and COPD patients might 
not benefit from these drugs (25,26). In the present study 
serum ECP and MPO levels were higher in current smokers 
than in never-smokers, suggesting that smoking increases 
airway inflammation characterized by eosinophil and 
neutrophil activation. This is also in concordance with the 
results of Jensen et al. (27), who have shown raised serum 
levels of ECP and lactoferrin, another neutrophil marker, in 
smokers., 
The role of increased neutrophil number in asthmatic 
airways is not clear. In a study by Nordman et al. (28) no 
significant differences in serum MPO values between 
normoreactive and hyper-reactive subjects in methacholine 
challenge were found. It has been suggested that in both 
allergic and non-allergic asthma, airway recruitment and 
activation of neutrophils occur parallel to eosinophil 
migration. Airway neutrophils might not, however, con- 
tribute to epithelial cell injury or to airway hyper- 
responsiveness in the steady state (29). On the other hand, 
neutrophils may induce tissue damage and participate in the 
shedding of the epithelium in status asthmaticus (30). 
Neutrophil recruitment, together with mast cells, may also 
contribute to the bronchoconstriction observed in occupa- 
tional asthma induced by grain dust (31). 
No differences were found between the study groups in 
baseline urine LTE* excretion. Some previous studies have 
reported higher urinary LTE4 levels in aspirin-sensitive 
asthmatics as compared to aspirin-tolerant asthmatics and 
healthy controls (14,15). One possible reason for the 
discrepancy is that in the present study patients were 
considered aspirin-sensitive according to their history and 
no provocations were performed. The measurement of 
urinary LTE4 in a single sample did not predict bronchial 
hyper-responsiveness, which confirms previous results 
obtained by Smith et al. (14) Bronchial provocation with 
specific allergen in atopic asthmatics induces a prompt 
increase in cysteinyl-leukotrience release which is reflected 
in increased urinary LTE4 excretion during the first few 
hours after the challenge (32). Enhanced urinary LTE4 
excretion has also been reported after aspirin challenge in 
aspirin-intolerant asthmatics, but methacholine challenge 
producing comparable bronchial obstruction has not been 
shown to alter eicosanoid excretion (15), as has provocation 
with histamine (32). In the present case, LTE4 excretion was 
not altered during the 2 h following methacholine challenge 
in hyper-reactive subjects but was elevated in non-hyper- 
reactive subjects. The largest increase was found in subjects 
with aspirin intolerance causing urticaria or angioedema, 
whereas the least (if any) increase was found in patients 
with asthma (groups 1 and 3). The reason for these results is 
not clear. The data in the present study suggest that higher 
doses of methacholine (6900 ug) provoke extrapulmonary 
cysteinyl-leukotriene production in non-hyper-reactive sub- 
jects (possibly in the skin, especially in aspirin-intolerant 
patients). 
The present data which suggest a negligible role of 
leukotrienes in bronchial hyper-responsiveness, are compli- 
cated by the findings of a beneficial clinical action of 5- 
lipoxygenase inhibitor zileuton (33) and a cysteinyl- 
leukotriene receptor antagonist pranlukast (34). A single 
oral dose of zileuton (400 mg) is found to increase PC2,, to 
histamine by 2.1 doubling doses and the PDzo to 
ultrasonically nebulized distilled water 1.3 doubling doses 
(33). These results, need, however, to be confirmed with a 
larger number of subjects with treatment given both acutely 
and long-term (35). With the leukotriene receptor antago- 
nist pranlukast, a small but significant reduction (from 0.30 
to 0,48 mg ml-‘) in methacholine responsiveness was 
observed after l-week of treatment in asthmatic patients 
(34). Our present data suggest that increased cysteinyl- 
leukotriene synthesis is not associated with bronchial 
hyper-responsiveness. Therefore other mechanisms, e.g. 
increased reactivity to leukotrienes rather than increased 
leukotriene synthesis, might explain the mediator role of 
cysteinyl-leukotrienes in bronchial hyper-responsiveness, as 
would indeed be implied by therapeutic interventions with 
5-liopoxygenase inhibitors and leukotriene receptor an- 
tagonists. 
In conclusion, the present results indicate that serum 
ECP and MPO, but not urinary LTE4, predict bronchial 
hyper-responsiveness to methacholine. The smoking history 
has to be taken into account when these inflammation 
parameters are used in clinical practice. 
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